CD276 and pancreatic adenocarcinoma: B7-H3, also known as the CD276 antigen, was targeted by CAR T-cells in pancreatic adenocarcinoma in vitro and a metastatic xenograft mouse model, which proved efficacy (Du et al., 2019).